Cargando…
Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology
To assess the relevance of MYCN amplification and bone lesions in stage 4 neuroblastoma (NB) in infants aged <1 year, 51 infants with stage 4 NB were enrolled. Three groups of patients were defined according to the type of metastases and the resectability of the primary tumour. Group I comprised...
Autores principales: | Minard, V, Hartmann, O, Peyroulet, M C, Michon, J, Coze, C, Defachelle, A S, Lejars, O, Perel, Y, Bergeron, C, Boutard, P, Leverger, G, Stephan, J L, Thyss, A, Chastagner, P, Couillault, G, Devalck, C, Lutz, P, Mechinaud, F, Millot, F, Plantaz, D, Rialland, X, Rubie, H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363565/ https://www.ncbi.nlm.nih.gov/pubmed/10993641 http://dx.doi.org/10.1054/bjoc.2000.1412 |
Ejemplares similares
-
Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
por: Rubie, H., et al.
Publicado: (1998) -
Treatment of stage 4s neuroblastoma – report of 10 years' experience of the French Society of Paediatric Oncology (SFOP)
por: Schleiermacher, G, et al.
Publicado: (2003) -
Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy
por: Rubie, H, et al.
Publicado: (2003) -
Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN
por: Guimier, Anne, et al.
Publicado: (2014) -
Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification
por: Schleiermacher, G, et al.
Publicado: (2007)